메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Rising Through Challenge: Living Phoenix's 2026 New Year Message POGMENT Biomimetic Collagen

CHENGDU, China, Jan. 1, 2026 -- As the Year of the Horse begins, bringing new momentum and promise, Living Phoenix—a pioneer in next-generation biomaterials—wishes all friends, partners, and users a joyful New Year. May you stay young, steady, and ready to gallop forward into 2026. Qin Xingjiong, founder of Living Phoenix, was invited as a representative of the innovation team to attend the AbbVie & Allergan China Open Day, where he shared insights on recent advancements and industry applications in trimeric collagen technology. From User Experience to Trust&n
- 김갑성 기자
- 2026-01-01 12:36
POGMENT Biomimic Collagen Reacquired Recognition, Founder Appointed as Industrial Mentor for Master's Students at East China Normal University, Awarded 2025 Innovation Leadership Award

CHENGDU, China, Dec. 31, 2025 -- On December 27, the 2025 Master of Engineering Management (MEM) Industry Mentor Orientation and Appointment Ceremony was held at the Wenshi Building on the Putuo Campus of East China Normal University (ECNU), located at No. 3663 Zhongshan North Road, Putuo District, Shanghai. Qin Xingjiong, founder of LivingPhoenix Regenerative Technology also chairman of the High-Tech & Supply Chain Branch of the China Association of Plastic Surgery, was formally appointed as an industry mentor for master's students. Professor He Jiaxun—PhD supervisor, prof
- 김갑성 기자
- 2025-12-31 17:21
Life-Space TrioBiotic Series Lands in Southeast Asia, Revolutionizing Gut Health with Triple-Action Formula

BANGKOK, Dec. 31, 2025 -- A significant shift is underway in the regional health and wellness landscape as the innovative Life-Space TrioBiotic supplement series officially enters the Southeast Asian market. The launch introduces a cutting-edge "three-in-one" approach to gut health, combining prebiotics, probiotics, and postbiotics in a single daily dose. The world of health and wellness has been fundamentally transformed by the pivotal role of Probiotics in supporting gut health and overall well-being. Over the past decade, we have witnessed an explosive surge in probiotic-b
- 김갑성 기자
- 2025-12-31 15:46
KLMBio Accelerates Global Expansion in Bone Graft Market with Human Tissue-Based Medical Devices

SEOUL, South Korea, Dec. 31, 2025 -- KLMBio, a manufacturer and exporter of human tissue-based medical devices, is accelerating its global business expansion by strengthening its high-value tissue-based product portfolio to target the rapidly growing global bone graft market. The global bone graft market is a high-growth medical device sector, driven by steadily increasing usage in orthopedic surgery, spinal procedures, and dental implants. The market is projected to reach approximately USD 6.66 billion by 2032. In particular, human tissue-based products continue to gain market prefere
- 김갑성 기자
- 2025-12-31 12:44
Qiming Venture Partners' Insilico Medicine Successfully Lists on Hong Kong Stock Exchange

SHANGHAI, Dec. 31, 2025 -- Insilico Medicine (03696.HK), a global leader in AI-driven drug discovery and a portfolio company of Qiming Venture Partners, today successfully listed on the Hong Kong Stock Exchange (HKEX). The listing marks the largest biotech IPO on the Hong Kong stock market in 2025. With an issue price of HK$ 24.05 per share, Insilico Medicine opened at HK$35.00 per share, representing a market capitalization of approximately HK$ 19.51 billion. Qiming Venture Partners is one of Insilico Medicine's most important institutional investors. Qiming Venture Partners led the C
- 김갑성 기자
- 2025-12-31 08:55
Entering the New Year, VARON Strengthens Commitment to Dependable Oxygen Support

NEW YORK, Dec. 31, 2025 -- As the new year begins, it offers a meaningful moment to reflect on shared progress and renewed responsibility in respiratory care. Over the past year, VARON has continued to focus on what matters most—reliability, accessibility, and compassion-driven action that supports real people and real needs. A Year Shaped by Reliability and Everyday Care The past year reinforced the growing importance of dependable oxygen therapy solutions. For many individuals and families, access to an oxygen concentrator for home use has become essentia
- 김갑성 기자
- 2025-12-31 07:34
Mabwell Announces First Patient Dosed in Phase II Trial of Anti-IL-11 Antibody for Pathological Scarring

SHANGHAI, Dec. 30, 2025 -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the Phase II clinical trial of its self-developed innovative anti-IL-11 monoclonal antibody (R&D code: 9MW3811) for pathological scarring recently completed the first patient dosing in China, becoming the world's first IL-11 targeting drug candidate to initiate clinical trials for pathological scarring. This Phase II clinical trial (CTR20254857) aims to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of 9
- 김갑성 기자
- 2025-12-30 22:00
China's Sleep Technology Pioneer Sleemon Draws Increasing Interest from the Global AI Community

SHAOXING, China, Dec. 30, 2025 -- A long-established household brand in China with a comparatively limited international profile, Sleemon Healthy Sleep Technology Co., Ltd. is gaining attention from the global technology community as it expands its focus on advanced sleep technology solutions. Founded in 1984, Sleemon was the first mattress manufacturer in China to list publicly (SSE: 603008). While the company adopted its current corporate name in recent years, it has long been recognized in the domestic market for its leadership and sustained investment in sleep technology. In
- 김갑성 기자
- 2025-12-30 21:54
The "Eastern Wisdom" of Aging: How Taikang's "New Life Insurance" Responds to a Global Challenge?

SHANGHAI, Dec. 30, 2025 -- Under the global background of ageing people, WallstreetCN reported how TaiKang play its wisdom in new-life-insurance. In 2014, journalists from Japan's NHK documented the phenomenon of A Society Without Bonds, portraying how the elderly in an atomized society—devoid of social, familial, or community ties—gradually become isolated and ultimately pass away alone. A decade later, the Japanese drama Two in the Neighborhood (Douban rating 9.3) offers a starkly different narrative. Its two 55-year-old female protagonists no longer treat aging with tragic s
- 김갑성 기자
- 2025-12-30 19:34
Insilico Medicine Lists on Hong Kong Stock Exchange, Showing AI Drug Discovery Momentum with 2025's Largest Hong Kong Biotech IPO

HONG KONG, Dec. 30, 2025 -- Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), is successfully listed on the Hong Kong Stock Exchange today, becoming the first AI-driven biotech company to go public in Main Board under Chapter 8.05 listing rules of the HKEX. This initial public offering (IPO) raised a total of HKD 2.277 billion, achieving the largest biotech IPO in Hong Kong this year, as in the size of fundraising. "With this massively oversubscribed listing we set several world's firsts
- 김갑성 기자
- 2025-12-30 17:00

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2026-01-01_THU

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 01월 01일 16시 00분